Aktuellt
SENASTE
Redeye comments on Lipigon's Q2 report 2024. The most significant event since our last update was the launch of Marea Therapeutics. We discuss how patient recruitment to the phase II study of Lipisense is ongoing and why it appears to have been slightly delayed.
LÄS MER
